Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Payel Chatterjee et al.|npj Precision Oncology|2023Cited by 26
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinomaMarwah Al-Aloosi, Carla Grandori, Lauren Appleyard et al.|Frontiers in Oncology|2024Cited by 8
Predictive value of a CLIA-approved organoid based drug sensitivity test.Astrid Margossian, Carla Grandori, Annie Richardson et al.|Journal of Clinical Oncology|2020Cited by 6
A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.Astrid Margossian, Carla Grandori, Madison Pollastro et al.|Journal of Clinical Oncology|2021Cited by 4
Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilitiesGoldie Y.L. Lui, Carla Grandori, Anne B. Richardson et al.|Cancer Research|2021Cited by 4